Literature DB >> 16157204

Cytogenetic findings in clear cell chondrosarcoma.

Jun Nishio1, John D Reith, Akira Ogose, Gary Maale, James R Neff, Julia A Bridge.   

Abstract

Clear cell chondrosarcoma is a rare cartilaginous tumor of low-grade malignancy that most often arises in the epiphysis of long bones in the third and fourth decades of life. Cytogenetic studies of clear cell chondrosarcoma are few. In this study, the cytogenetic findings of 4 cases of clear cell chondrosarcoma are presented. Clonal chromosomal abnormalities were detected in 3 cases. A tumor specific anomaly was not identified, however, extra copies of chromosome 20 and loss or rearrangements of 9p appear to be recurrent.

Entities:  

Mesh:

Year:  2005        PMID: 16157204     DOI: 10.1016/j.cancergencyto.2005.03.003

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  Clear cell chondrosarcoma of the talus in Von Hippel-Lindau disease: a rare tumor in an unusual location and uncommon co-presentation.

Authors:  Min Jeong Song; Kyu Yeoun Won; Soonchan Park
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

2.  Chondrosarcoma: with updates on molecular genetics.

Authors:  Mi-Jung Kim; Kyung-Ja Cho; Alberto G Ayala; Jae Y Ro
Journal:  Sarcoma       Date:  2011-02-15

3.  An unusual case of clear cell chondrosarcoma with very late recurrence and lung metastases, 29 years after primary surgery.

Authors:  Minna Laitinen; Jyrki Nieminen; Toni-Karri Pakarinen
Journal:  Case Rep Orthop       Date:  2014-07-20

4.  Clear cell chondrosarcoma is an underestimated tumor: Report of 7 cases and meta-analysis of the literature.

Authors:  Alexander Klein; Felix Tauscher; Christof Birkenmaier; Andrea Baur-Melnyk; Thomas Knösel; Volkmar Jansson; Hans Roland Dürr
Journal:  J Bone Oncol       Date:  2019-10-31       Impact factor: 4.072

Review 5.  Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.

Authors:  Katia Scotlandi; Claudia Maria Hattinger; Evelin Pellegrini; Marco Gambarotti; Massimo Serra
Journal:  Cells       Date:  2020-04-14       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.